

Please try another search
Veru Inc. is an oncology biopharmaceutical company. The Company is focused on developing medicines for the management of breast and prostate cancers. The Company's FC2 segment consists of its commercial product, FC2. The Pharmaceuticals segment includes activities related to multiple drug products under clinical development and ENTADFI, a treatment for benign prostatic hyperplasia. It has a commercial Sexual Health Division, which includes two products, such as ENTADFI, a treatment for benign prostatic hyperplasia (BPH), and the FC2 Female Condom (Internal Condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.
Name | Age | Since | Title |
---|---|---|---|
Mitchell S. Steiner | 61 | 2016 | Chairman, President & CEO |
Harry Fisch | 63 | 2016 | Vice Chairman & Chief Corporate Officer |
Mario Eisenberger | 72 | 2016 | Independent Director |
Xiaoqin Lu | 47 | 2021 | Independent Director |
Michael L. Rankowitz | 64 | 2018 | Independent Director |
Grace S. Hyun | 51 | 2020 | Independent Director |
Andrew Sproule Love | 79 | 2013 | Board Observer |
David D. Ho | 69 | 2023 | Chairman of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review